Fledgling biotech Syntimmune looks to take flight in the clinic with a new CEO and a slightly less virtual business model
Syntimmune is still a largely untethered, virtual biotech with a tiny crew of staffers backed by a platoon of consultants. But today it’s just a little less virtual and a little more focused on building a company.
David de Graaf, an experienced R&D vet, is leaving his role as a venture partner at Apple Tree and taking the helm at the biotech, which is concentrating on ramping up a slate of Phase Ib/IIa studies for a pipeline of drugs targeting IgG-mediated autoimmune diseases by blocking FcRn-IgG interactions. Burt Adelman, former R&D chief at Dyax, is joining the board. And the team will have an extra $8 million in fresh funding to get the clinical game underway in earnest.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.